Selected stock price target news of the day - July 8th, 2025

By: Matthew Otto

CleanSpark Reaches 50 EH/s Mid-Year Target; Reports June Production and Treasury Data

CleanSpark reported reaching its mid-year operational hashrate target of 50 exahashes per second (EH/s) in June 2025, according to its unaudited monthly update released July 7. The increase represents a 9.6% rise from May levels and reflects the addition of over 10 EH/s of capacity across four U.S. states.

CleanSpark mined 685 bitcoin during the month. This is averaging 22.82 BTC per day, with a peak single-day production of 23.97 BTC. As of June 30, the company’s deployed fleet consisted of 241,227 machines, operating at an average efficiency of 16.15 joules per terahash (J/Th) and maintaining an average operational hashrate of 45.3 EH/s. CleanSpark’s total bitcoin holdings stood at 12,608 BTC, including 2,533 BTC posted as collateral. This figure places it seventh among publicly traded companies worldwide, based on July 2025 data from BitcoinTreasuries.net.

In the same period, CleanSpark sold 578.51 BTC, generating approximately $61.24 million in gross proceeds at an average sale price of $105,860 per bitcoin. This was $446 above the reported monthly volume-weighted average price (VWAP) of $105,414, not accounting for additional premiums received from derivative strategies. Power metrics for the month showed 987 megawatts (MW) of capacity under contract, with 808 MW in use. An additional 179 MW of power has been secured to support future hashrate expansion.

Analyst Reiterates Rating After Milestone and Performance Update

Chardan Capital analyst James McIlree maintained a Buy rating and a $20 price target.

Which Analyst has the best track record to show on CLSK?

Analyst Reginald Smith (JPMORGAN) currently has the highest performing score on CLSK with 7/8 (87.5%) price target fulfillment ratio. His price targets carry an average of $4.7 (50.54%) potential upside. CleanSpark stock price reaches these price targets on average within 39 days.

WNS to Be Acquired by Capgemini to Advance AI-Driven Business Services

WNS Holdings has agreed to be acquired by France-based Capgemini SE in an all-cash transaction valued at $3.3 billion, or $76.5 per share. The offer represents a 17% premium over WNS’s closing share price of approximately $65.35 on July 3, 2025, and excludes the company’s financial debt. According to Capgemini’s announcement on July 8, the deal is expected to close by the end of 2025, pending regulatory and customary approvals.

WNS reported $1.33 billion in revenue for fiscal year 2024 and employs over 59,000 people across 16 countries. Its operations include digital services, finance and accounting, customer experience, and data analytics. Key clients include multinational companies such as Coca-Cola, T-Mobile, and United Airlines. Capgemini noted that the integration is expected to align WNS with its global network—which includes over 340,000 employees and generated approximately $24.5 billion in revenue in 2024.

Analyst Downgrades Following Acquisition Announcement

Jefferies analyst Surinder Thind downgraded from Buy to Hold and the price target from $80 to $76.5.
Baird analyst David Koning lowered his rating from Outperform to Neutral and set a price target of $76.5.

Which Analyst has the best track record to show on WNS?

Analyst Surinder Thind (JEFFERIES) currently has the highest performing score on WNS with 3/4 (75%) price target fulfillment ratio. His price targets carry an average of $5.91 (12.04%) potential upside. WNS Holdings stock price reaches these price targets on average within 212 days.

Updated at 9:42 EST

UroGen Completes Enrollment for Phase 3 UTOPIA Trial of UGN-103

On July 7, 2025, UroGen Pharma announced completion of patient enrollment for its Phase 3 UTOPIA trial, which evaluates UGN-103 (mitomycin) for intravesical treatment of recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The study enrolled 99 patients across international sites.

UGN-103 incorporates RTGel®, a reverse-thermal hydrogel designed to enable sustained drug release in the bladder. The formulation differs from the approved ZUSDURI™ product in its manufacturing and preparation process. The single-arm trial involves 75 mg of UGN-103 administered weekly for six weeks. The primary endpoint is complete response rate at three months, with a 12-month follow-up for responders.

Bladder cancer is the sixth most common cancer in the United States, with 83,190 new cases estimated in 2025. Approximately 75% to 80% are non-muscle invasive, and a subset is classified as LG-IR, which is associated with frequent recurrence. UroGen received a Notice of Allowance for a UGN-103 patent in September 2024, with protection expected through December 2041.

Analyst Maintains Rating Following Trial Enrollment Milestone

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating and a $50 price target.

Which Analyst has the best track record to show on URGN?

Analyst Leland Gershell (OPPENHEIMER) currently has the highest performing score on URGN with 2/17 (11.76%) price target fulfillment ratio. His price targets carry an average of $5 (100.00%) potential upside. UroGen Pharma stock price reaches these price targets on average within 42 days.